Trial Information
Inflammation and Treatment of Bacterial Vaginosis Near Term
Inclusion Criteria:
- 32 weeks gestation or greater
- Multiparity
- No history of preterm birth
- English speaking
- Ability to provide informed consent
- Bacterial vaginosis by gram stain
Exclusion Criteria:
- Acute infections at any site
- Active autoimmune disease
- Current anti-inflammatory use
- Symptomatic bacterial vaginosis
- Previous adverse reaction to metronidazole
- Reports ongoing ethanol consumption
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Outcome Measure:
Levels of Interleukins 1 and 6 as well as Tumor Necrosis Factor Alpha
Outcome Time Frame:
3-5 days after start of treatment
Safety Issue:
Yes
Principal Investigator
Heather Norton, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Medical University of South Carolina
Authority:
United States: Institutional Review Board
Study ID:
HR # 17069
NCT ID:
NCT00720291
Start Date:
February 2006
Completion Date:
December 2009
Related Keywords:
- Bacterial Vaginosis
- Metronidazole
- BV
- Pregnancy
- Inflammation
- Vaginosis, Bacterial
Name | Location |
Medical University of South Carolina |
Charleston, South Carolina 29425-0721 |